A study was conducted to examine the patients with aortic stenosis (AS) and end-stage renal disease (ESRD) undergoing transcatheter and surgical aortic valve replacement (TAVR and SAVR), with a focus on contemporary national trends of comorbidities, outcomes, and health care resource utilization in this group.

The study showed that the TAVR patients, despite having higher comorbidity burden (anaemia, coronary artery disease, chronic pulmonary disease, congestive heart failure, cerebrovascular disease, and peripheral vascular disease) had lower inpatient mortality and complications (ST-elevation myocardial infarction, pneumonia, pneumothorax, pulmonary embolism, cardiogenic shock, cardiac arrest, and need for mechanical ventilators and vasopressors). The duration and cost of hospital stay reduced with TAVR; but remained unchanged with SAVR.

The authors concluded that among patients with aortic stenosis and end stage renal disease, despite providing therapy to subjects with higher comorbidity burden, TAVR was linked with lower inpatient mortality, complications, length of stay, cost of care, and higher home disposition rates when compared with surgical aortic valve replacement.

Reference

1. Khan MZ, Khan MU, Kalra A, Krupica T, Kalusli E, Khan SU. Transcatheter versus surgical aortic valve replacement in patients with end stage renal disease. 7 July 2020. DOI: https://doi.org/10.1002/ccd.29109